Seattle Genetics Gains Another FDA Approval

Seattle Genetics Gains Another FDA Approval


Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration had approved its Adcetris in combination with chemotherapy in adults with previously untreated Stage III or IV classical Hodgkin lymphoma. This is the fifth approval for the drug, and some analysts predict it will edge ever-closer to blockbuster status-$1 billion in annual sales-but some, as well as some oncologists, are skeptical.



from Biotech News